Cardiovascular events after polychemotherapy of multiple myeloma: modern ways to diagnostics
DOI:
https://doi.org/10.14739/2409-2932.2020.1.198217Keywords:
multiple myeloma, cardiovascular events, chemotherapy, diagnostics, prognostic factorsAbstract
Heart dysfunction that occurred after using cytostatic drugs and monoclonal antibodies may be a limit factor in the treatment of multiple myeloma. Side effects of chemotherapy include hypotension, hypertension, arrhythmias, conduction disturbances, pericarditis, thromboembolic events, heart failure, death.
The risk of cardiotoxicity may be increased by some factors that include drug exposure, age, history of heart diseases, arterial hypertension, drug combination, previous radiotherapy or chemotherapy. It’s important to detect cardiovascular toxicity before the appearance of clinical signs of heart and vessel disturbance. The role of markers in the elicitation of risk groups of cardiovascular events is uncertain yet.
Early diagnostics and definition of prognostic factors of cardiovascular toxicity appeared after polychemotherapy of oncohematological diseases are important and not solve problems.
multiple myeloma, cardiovascular events, chemotherapy, diagnostics, prognostic factors.
References
Bazyka, D. A., Gudzenko, N. A., Dyagil, I. S., Babkina, N. G., Chumak, V. V., Bakhanova, E. V., Paramonov, V. V., & Romanenko A. Ye. (2013). Multiple myeloma among chornobyl accident clean, up workers – state and perspectives of analytical study. Problemy radiatsiinoi medytsyny ta radiobiolohii, (18), 169-172. [in Ukrainian].
Pazina, T. Yu., Korneva, E. A., Orlov, D. S., & Shamova, O. V. (2017). Mnozhestennaja mieloma: patogenez i novye podhody k terapii [Multiple myeloma: pathogenesis and new approaches to therapy]. Patogenez, 15(1), 4-10. [in Russian].
Osborne, T. R., Ramsenthaler, C., de Wolf-Linder, S., Schey, S. A., Siegert, R. J., Edmonds, P. M., & Higginson, I. J. (2014). Understanding what matters most to people with multiple myeloma: a qualitative study of views on quality of life. Bmc Cancer, 14, Article 496. https://doi.org/10.1186/1471-2407-14-496
Ewer, M. S., & Ewer, S. M. (2015). Cardiotoxicity of anticancer treatments. Nature Reviews Cardiology, 12(9), 547-558. https://doi.org/10.1038/nrcardio.2015.65
Heckmann, M. B., Doroudgar, S., Katus, H. A., & Lehmann, L. H. (2018). Cardiovascular adverse events in multiple myeloma patients. Journal of Thoracic Disease, 10, S4296-S4305. https://doi.org/10.21037/jtd.2018.09.87
De Stefano, V., Za, T., & Rossi, E. (2014). Venous Thromboembolism in Multiple Myeloma. Seminars in Thrombosis and Hemostasis, 40(3), 338-347. https://doi.org/10.1055/s-0034-1370793
Cornell, R. F., & Kassim, A. A. (2016). Evolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexity. Bone Marrow Transplantation, 51(4), 479-491. https://doi.org/10.1038/bmt.2015.307
Vatutin, N. T., Sklyanaya, E. V., Shevelek, A. N., Smirnova, A. S., El'-Khatib, M. A., Gritsenko, Yu. P., Kolesnikov, V. S., & Taratorina, A. A. (2017). Preparaty, vyzyvayushchie ili ukhudshayushchie techenie serdechnoi nedostatochnosti. Obzor rekomendatsii Amerikanskoi assotsiatsii serdtsa [Drugs That May Cause or Exacerbate Heart Failure. A Scientific Statement from the American Heart Association. Circulation]. Praktychna anhiolohiia, (1), 52-65. [in Ukrainian].
Kevane, B., Crowley, M. P., Bolster, M., & Gilligan, O. (2014). Myeloma Relapse Involving the Heart and Presenting As Acute Cardiac Failure. Journal of Clinical Oncology, 32(18), E67-E68. https://doi.org/10.1200/jco.2012.47.6713
Fowler, N. H., Cheah, C. Y., Gascoyne, R. D., Gribben, J., Neelapu, S. S., Ghia, P., … Dunleavy, K. (2016). Role of the tumor microenvironment in mature B-cell lymphoid malignancies. Haematologica, 101(5), 531-540. https://doi.org/10.3324/haematol.2015.139493
Lakomkin, V. L., Abramov, A. A., Gramovich, V. V., Vyborov, O. N., Lukoshkova, E. V., Ermishkin, V. V., & Kapelko, V. I. (2017). Dinamika formirovaniya sistolicheskoi disfunktsii serdtsa pri doksorubitsinovoi kardiomiopatii [The Time Course of Formation Of Systolic Dysfunction of the Heart in Doxorubicin Cardiomyopathy]. Kardiologiia, 57(1), 59-64. [in Russian]. https://doi.org/10.18565/cardio.2017.1.59-64
Akazawa, H. (2017). Cardiotoxicity of cancer chemotherapy – mechanisms and Therapeutic Approach. Gan to kagaku ryoho. Cancer & chemotherapy, 44(13), 2058-2063.
(2017). Likuvannia onkolohichnykh zakhvoriuvan i sertsevo-sudynna toksychnist: Tochka zoru Yevropeiskoho tovarystva kardiolohiv. Ch. 1 [The perspective of the European Society of Cardiologists. Cancer treatment and cardiovascular toxicity. Рart. 1]. Sertse i sudyny, (2), 11-19. [in Ukrainian].
Suter, T. M., & Ewer, M. S. (2013). Cancer drugs and the heart: importance and management. European Heart Journal, 34(15), 1102-1111. https://doi.org/10.1093/eurheartj/ehs181
Postnikov, S. S., Gratianskaya, A. N., & Kostyleva, M. N. (2015). Lekarstvennye bolezni serdtsa i sosudov [Drug diseases of heart and blood vessels]. Pediatria, 94(2), 169-174. [in Russian].
Anokhin, V. N., Chushkin, M. I., & Kolganov, A. V. (2011). Antratsiklinovaya kardiomiopatiya [Anthracycline cardiomyopathy]. Terapevticheskiy arkhiv, 83(10), 72-76. [in Russian].
Amosova, K. M. (2016). Kardiomiopatii: suchasnyi pohliad na pytannia klasyfikatsii, etiolohii, diahnostyky ta dyferentsialnoi diahnostyky [Cardiomyopathies: modern view on the issues of classification, etiology, diagnosis and differential diagnosis. Part 1]. Sertse i sudyny, 2, 7-18. [in Ukrainian].
Ritchie, D. S., Seymour, J. F., Roberts, A. W., Szer, J., & Grigg, A. P. (2001). Acute left ventricular failure following melphalan and fludarabine conditioning. Bone Marrow Transplantation, 28(1), 101-103. https://doi.org/10.1038/sj.bmt.1703098
Skrypnyk, I. M., Maslova, H. S., & Lymanets, T. V. (2016). Ishemichna khvoroba sertsia yak faktor ryzyku antratsyklinindukovanoi kardiotoksychnosti [Ischemic heart disease as a risk factor for anthracycline-induced cardiotoxicity]. Vrachebnoe delo, 5-6, 47-52. [in Ukrainian].
Gulati, A., Jabbour, A., Ismail, T. F., Guha, K., Khwaja, J., Raza, S., … Prasad, S. K. (2013). Association of Fibrosis With Mortality and Sudden Cardiac Death in Patients With Nonischemic Dilated Cardiomyopathy. Jama-Journal of the American Medical Association, 309(9), 896-908. https://doi.org/10.1001/jama.2013.1363
Plana, J. C., Galderisi, M., Barac, A., Ewer, M. S., Ky, B., Scherrer-Crosbie, M., … Lancellotti, P. (2014). Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. European Heart Journal-Cardiovascular Imaging, 15(10), 1063-1093. https://doi.org/10.1093/ehjci/jeu192
Castel, M., Despas, F., Modesto, A., Gales, C., Honton, B., Galinier, M., Senard, J. M., & Pathak, A. (2013). Cardiotoxicity of chemotherapies. Presse Med, 42(1), 26-39. https://doi.org/10.1016/j.lpm.2012.04.014
Willis, M. S., & Patterson, C. (2013). Mechanisms of Disease Proteotoxicity and Cardiac Dysfunction - Alzheimer's Disease of the Heart? New England Journal of Medicine, 368(5), 455-464. https://doi.org/10.1056/NEJMra1106180
Richardson, P. G., Sonneveld, P., Schuster, M. W., Irwin, D., Stadtmauer, E. A., Facon, T., … Investigators, A. (2005). Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. New England Journal of Medicine, 352(24), 2487-2498. https://doi.org/10.1056/NEJMoa043445
Stewart, A. K., Rajkumar, S. V., Dimopoulos, M. A., Masszi, T., Spicka, I., Oriol, A., … Investigators, A. (2015). Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma. New England Journal of Medicine, 372(2), 142-152. https://doi.org/10.1056/NEJMoa1411321
Moreau, P., Masszi, T., Grzasko, N., Bahlis, N. J., Hansson, M., Pour, L., … Grp, T.-M. S. (2016). Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. New England Journal of Medicine, 374(17), 1621-1634. https://doi.org/10.1056/NEJMoa1516282
Nesen, A. O. (2014). Khronichni neinfektsiini zakhvoriuvannia: aktsent na komorbidnist i pidvyshchenyi kardiovasuliarnyi ryzyk [Chronic non-communicable diseases: accent on comorbidity and increased cardiovascular risk]. Ukrainskyi terapevtychnyi zhurnal, (2), 26-32. [in Ukrainian].
Cardinale, D., Biasillo, G., Salvatici, M., Sandri, M. T., & Cipolla, C. M. (2017). Using biomarkers to predict and to prevent cardiotoxicity of cancer therapy. Expert Review of Molecular Diagnostics, 17(3), 245-256. https://doi.org/10.1080/14737159.2017.1283219
Chow, E. J., Chen, Y., Kremer, L. C., Breslow, N. E., Hudson, M. M., Armstrong, G. T., … Yasui, Y. (2015). Individual Prediction of Heart Failure Among Childhood Cancer Survivors. Journal of Clinical Oncology, 33(5), 394-402. https://doi.org/10.1200/jco.2014.56.1373
Lipshultz, S. E., Adams, J., Colan, S. D., Constine, L. S., Herman, E. H., Hsu, D. T., … Council Nutr Phys Activity, M. (2013). Long-term Cardiovascular Toxicity in Children, Adolescents, and Young Adults Who Receive Cancer Therapy: Pathophysiology, Course, Monitoring, Management, Prevention, and Research Directions A Scientific Statement From the American Heart Association. Circulation, 128(17), 1927-1995. https://doi.org/10.1161/CIR.0b013e3182a88099
Solodiannikova, O. I., Golovko, T. S., Lavryk, G. V., & Shevchuk, L. A. (2012). Vozmozhnosti ekhokardiografii v otsenke kardiotoksichnosti khimioterapevticheskogo lecheniya bol'nykh onkologicheskogo profilya: sostoyanie problemy v literature, rezul'taty sobstvennykh issledovanii [Echocardiography capability in assessment of chemotherapy’s cardiotoxicity of oncologic patients (literature review, results of own examinations)]. Klinicheskaya onkologiya, (8), 144-150. [in Russian].
Fandeev, O. A., Vasechkin, S. S., Alekhin, M. N., Odintsov, S. V., Kallistov, V. E., & Sidorenko, B. A. (2011). Klinicheskoe znachenie kardiotoksichnosti antratsiklinov: sovremennye podkhody k diagnostike, profilaktike i lecheniyu [Clinical Value of Antracycline Toxicity: Modern Approaches to Diagnosis, Prevention, and Treatment]. Kardiologiia, 51(7), 40-46. [in Russian].
Chernov, V. I., Kravchuk, T. L., Zelchan, R. V., & Goldberg, V. E. (2015). Radionuklidnye metody issledovaniya v otsenke kardiotoksichnosti antratsiklina [Radionuclide Methods in the Assessment of Anthracycline-Induced Cardiotoxicity]. Kardiologiia, 55(7), 57-62. [in Russian].
Bellenger, N. G., Burgess, M. I., Ray, S. G., Lahiri, A., Coats, A. J. S., Cleland, J. G. F., Pennell, D. J., & Christmas Study Steering Comm, I. (2000). Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance - Are they interchangeable? European Heart Journal, 21(16), 1387-1396. https://doi.org/10.1053/euhj.2000.2011
Vogel-Claussen, J., Finn, J. P., Gomes, A. S., Hundley, G. W., Jerosch-Herold, M., Pearson, G., … Bluemke, D. A. (2006). Left ventricular papillary muscle mass: Relationship to left ventricular mass and volumes by magnetic resonance imaging. Journal of Computer Assisted Tomography, 30(3), 426-432. https://doi.org/10.1097/00004728-200605000-00013
Thavendiranathan, P., Walls, M., Giri, S., Verhaert, D., Rajagopalan, S., Moore, S., Simonetti, O. P., & Raman, S. V. (2012). Improved Detection of Myocardial Involvement in Acute Inflammatory Cardiomyopathies Using T2 Mapping. Circulation-Cardiovascular Imaging, 5(1), 102-110. https://doi.org/10.1161/circimaging.111.967836
Plana, J. C., Galderisi, M., Barac, A., Ewer, M. S., Ky, B., Scherrer-Crosbie, M., … Lancellotti, P. (2014). Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. European Heart Journal-Cardiovascular Imaging, 15(10), 1063-1093. https://doi.org/10.1093/ehjci/jeu192
Thavendiranathan, P., Grant, A. D., Negishi, T., Plana, J. C., Popovic, Z. B., & Marwick, T. H. (2013). Reproducibility of Echocardiographic Techniques for Sequential Assessment of Left Ventricular Ejection Fraction and Volumes Application to Patients Undergoing Cancer Chemotherapy. Journal of the American College of Cardiology, 61(1), 77-84. https://doi.org/10.1016/j.jacc.2012.09.035
Samura, B. B., Kolesnyk, Yu. M., & Syvolap, V. V. (2014). Znachennia tsyrkuliuiuchoho halektynu-3 v prohnozuvanni kardiovaskuliarnykh podii u patsiientiv iz khronichnoiu limfotsytarnoiu leikemiieiu v remisii [Value of circulating galectin-3 for prognosis of cardiovascular events in patients with chronic lymphocytic leukemia in remission]. Zaporozhye medical journal, 2014, (6). 44-47. [in Ukrainain].
Sawaya, H., Sebag, I. A., Plana, J. C., Januzzi, J. L., Ky, B., Tan, T. C., … Scherrer-Crosbie, M. (2012). Assessment of Echocardiography and Biomarkers for the Extended Prediction of Cardiotoxicity in Patients Treated With Anthracyclines, Taxanes, and Trastuzumab. Circulation-Cardiovascular Imaging, 5(5), 596-603. https://doi.org/10.1161/circimaging.112.973321
Voigt, J. U., Pedrizzetti, G., Lysyansky, P., Marwick, T. H., Houle, H., Baumann, R., … Badano, L. P. (2015). Definitions for a common standard for 2D speckle tracking echocardiography: consensus document of the EACVI/ASE/Industry Task Force to standardize deformation imaging. European Heart Journal-Cardiovascular Imaging, 16(1), 1-11. https://doi.org/10.1093/ehjci/jeu184
Vizіr, V. A., Popov, V. V., Kopitsa, N. P., & Voloshyna, I. N. (2011). Biomarkery pri serdechnoi nedostatochnosti - novye orientiry lechebnoi taktiki? [Biomarkers in heart failure – new objectives of therapeutic tactics?]. Sertse i sudyny, (2), 108-113. [in Russian].
Berezin, A. E. (2015). Biologicheskie markery v diagnostike, prognozirovanii i otsenke effektivnosti terapii serdechnoi nedostatochnosti s sokhranennoi i snizhennoi kontraktil'noi funktsiei [Biological markers in the diagnosis, prediction and evaluation of the effectiveness of heart failure therapy with preserved and reduced contractile function]. Sertseva nedostatnist, (2), 16-27. [in Russian].
Cardinale, D., Colombo, A., Lamantia, G., Colombo, N., Civelli, M., De Giacomi, G., … Cipolla, C. M. (2010). Anthracycline-Induced Cardiomyopathy Clinical Relevance and Response to Pharmacologic Therapy. Journal of the American College of Cardiology, 55(3), 213-220. https://doi.org/10.1016/j.jacc.2009.03.095
Specchia, G., Buquicchio, C., Pansini, N., Di Serio, F., Liso, V., Pastore, D., … Liso, A. (2005). Monitoring of cardiac function on the basis of serum troponin I levels in patients with acute leukemia treated with anthracyclines. Journal of Laboratory and Clinical Medicine, 145(4), 212-220. https://doi.org/10.1016/j.lab.2005.02.003
Dorizzi, R. M., Caputo, M., Ferrari, A., Lippa, L., & Rizzotti, P. (2002). Comparison of serum and heparin-plasma samples in different generations of dimension troponin I assay. Clinical Chemistry, 48(12), 2294-2296.
Soker, M., & Kervancioglu, M. (2005). Plasma concentrations of NT-pro-BNP and cardiac troponin-I in relation to doxorubicin-induced cardiomyopathy and cardiac function in childhood malignancy. Saudi Medical Journal, 26(8), 1197-1202.
Suzuki, T., Hayashi, D., Yamazaki, T., Mizuno, T., Kanda, Y., Komuro, I., … Yazaki, Y. (1998). Elevated B-type natriuretic peptide levels after anthracycline administration. American Heart Journal, 136(2), 362-363. https://doi.org/10.1053/hj.1998.v136.89908
Maries, L., & Manitiu, I. (2013). Diagnostic and prognostic values of B-type natriuretic peptides (BNP) and N-terminal fragment brain natriuretic peptides (NT-pro-BNP). Cardiovascular Journal of Africa, 24(7), 286-289. https://doi.org/10.5830/cvja-2013-055
Yaris, N., Ceviz, N., Coskun, T., Akyuz, C., & Buyukpamukcu, M. (2002). Serum carnitine levels during the doxorubicin therapy. Its role in cardiotoxicity. Journal of Experimental & Clinical Cancer Research, 21(2), 165-170.
Del Pinto, R., & Ferri, C. (2018). Inflammation-Accelerated Senescence and the Cardiovascular System: Mechanisms and Perspectives. International Journal of Molecular Sciences, 19(12), Article 3701. https://doi.org/10.3390/ijms19123701
US Food and Drug Administration. (2013, July 1). 510(k) Substantial Equivalence Determination Decision Summary; K093758. http://www.accessdata.fda.gov/cdrh_docs/reviews/K093758.pdf
Syvolap, V. D., Lashkul, D. A. (2014). Vzaiemozviazky mizh rivnem markeriv fibrozu ST2, halektynu-3, strukturno-funktsionalnymy parametramy livoho shlunochka ta funktsiieiu nyrok pry khronichnii sertsevii nedostatnosti ishemichnoho henezu [The relationship between the level of markers of fi brosis ST2, galectin-3, structural, functional parameters of the left ventricle and renal function in patients with ischemic chronic heart failure]. Zaporozhye medical journal, 2014, (5), 13-17. [in Ukrainian]. https://doi.org/10.14739/2310-1210.2014.5.28742
Sano, H., Hsu, D. K., Apgar, J. R., Yu, L., Sharma, B. B., Kuwabara, I., Izui, S., & Liu, F. T. (2003). Critical role of galectin-3 in phagocytosis by macrophages. Journal of Clinical Investigation, 112(3), 389-397. https://doi.org/10.1172/jci200317592
Krzeslak, A., & Lippinska, A. (2004). Galectin-3 as a multifunctional protein. Cellular & Molecular Biology Letters, 9(2), 305-328.
Samura, B. (2015). Prognosticheskaja rol galektina-3 u pacientov so mnozhestvennoj mielomoj v remissii [The prognostic role of galectin-3 in patients with multiple myeloma in remission]. Zaporozhye Medical Journal, (4), 11-16. [in Russian]. https://doi.org/10.14739/2310-1210.2015.4.50298
van der Velde, A. R., Gullestad, L., Ueland, T., Aukrust, P., Guo, Y., Adourian, A., … de Boer, R. A. (2013). Prognostic Value of Changes in Galectin-3 Levels Over Time in Patients With Heart Failure Data From CORONA and COACH. Circulation-Heart Failure, 6(2), 219-226. https://doi.org/10.1161/circheartfailure.112.000129
Amin, H. Z., Amin, L. Z., & Wijaya, I. P. (2017). Galectin-3: A novel biomarker for the prognosis of heart failure. Clujul Medical, 90(2), 129-132. doi:10.15386/cjmed-751
Bentley, K., Franco, C. A., Philippides, A., Blanco, R., Dierkes, M., … Gerhardt, H. (2014). The role of differential VE-cadherin dynamics in cell rearrangement during angiogenesis. Nature Cell Biology, 16(4), 309-321. https://doi.org/10.1038/ncb2926
Samura, B. (2016). Galectin-3 as a predictor of statin treatment efficacy in patients with multiple myeloma. Georgian Medical News, 255, 56-61.
Samura, B. B. (2016). Predictive value of circulating N-Terminal Pro-Brain Natriuretic Protein and VE-Catherin in patients with regression of multiple myeloma. Biological Markers and Guided Therapy, 3(1), 125-132. http://dx.doi.org/10.12988/bmgt.2016.6413
Downloads
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)
